SCHEMBL28937050

SCHEMBL28937050

Cc1cc(N)nc(Oc2ccc(-c3ccc(F)cc3)nc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 2/20 0.41
▸ MAPK14 Q16539 2/20 0.41
▸ AURKA O14965 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ RET P07949 1/20 0.41
▸ MET P08581 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ MAP2K1 Q02750 1/20 0.41
▸ MAP4K2 Q12851 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ NTRK3 Q16288 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349922 0.79 MEN1 (0.43) ABL1MAPK14AURKANTRK1LCK
SCHEMBL22529957 0.79 MEN1 (0.43) ABL1MAPK14AURKANTRK1LCK
SCHEMBL22530094 0.79 KDM4E (0.43) ABL1MAPK14AURKANTRK1LCK
SCHEMBL29351821 0.79 KDM4E (0.43) ABL1MAPK14AURKANTRK1LCK
SCHEMBL26140408 0.75 MEN1 (0.39) ABL1MAPK14AURKANTRK1LCK
SCHEMBL28704648 0.73 KDM4E (0.41) ABL1MAPK14AURKANTRK1LCK
SCHEMBL22530943 0.72 MAPK8 (0.38) ABL1MAPK14AURKANTRK1LCK
SCHEMBL22529924 0.72 AURKA (0.38) ABL1MAPK14AURKANTRK1LCK
SCHEMBL29350344 0.72 MAPK8 (0.38) ABL1MAPK14AURKANTRK1LCK
SCHEMBL29352030 0.72 AURKA (0.38) ABL1MAPK14AURKANTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114007696-A Compounds for treating oncovirus-induced cancer and methods of use thereof 塞莱斯蒂亚生物技术股份公司 2022-02-01 — — CN disclosed
Send feedback